Antidepressant effect of combined ketamine and electroconvulsive therapy on patients with major depressive disorder: A randomized trial

Iranian Journal of Psychiatry and Behavioral Sciences

Volumn 9, Issue 3, 2015, Pages

  Alizadeh, Narges Shams ^a   Maroufi, Azad ^a   Nasseri, Karim ^a   Najafabadi, Seyed Hosein Sadeghi ^a   Taghiabad, Ali Mousavi ^a   Gharibi, Fardin ^a   Esfandiari, Gholam Reza ^a  

^a KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antidepressants; Electroconvulsive therapy; Ketamine

Indexed keywords

AMINES; ANESTHETICS; DELAY CONTROL SYSTEMS; ELECTROTHERAPEUTICS; RECOVERY; TIME DELAY;

ANTIDEPRESSANTS; COGNITIVE PERFORMANCE; ELECTROCONVULSIVE THERAPY; KETAMINE; MAJOR DEPRESSIVE DISORDER (MDD); RANDOMIZED CLINICAL TRIALS; RANDOMIZED TRIAL; RECOVERY PROCESS;

PATIENT TREATMENT;

ATROPINE; KETAMINE; PROPOFOL; SUXAMETHONIUM;

ADULT; AGED; AGITATION; ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; DSM-IV-TR; ELECTROCONVULSIVE THERAPY; FEMALE; HALLUCINATION; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MALE; MUSCLE RELAXATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 85012964696     PISSN: 17358639     EISSN: 17359287     Source Type: Journal    
DOI: 10.17795/ijpbs-1578     Document Type: Article

References (26)

1. Bosker FJ, Westerink BH, Cremers TI, Gerrits M, van der Hart MG, Kuipers SD, et al. Future antidepressants: what is in the pipeline and what is missing? CNS Drugs. 2004;18(11):705-32.
2. Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT. 2004;20(1):13-20.
3. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006;67 Suppl 6:16-22.
4. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-4.
5. Zarate CJ, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-64.
6. Liebrenz M, Borgeat A, Leisinger R, Stohler R. Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Med Wkly. 2007;137(15-16):234-6.
7. Krystal AD, Weiner RD, Dean MD, Lindahl VH, Tramontozzi L3, Falcone G, et al. Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. J Neuropsychiatry Clin Neurosci. 2003;15(1):27-34.
8. Loo C, Sainsbury K, Martin D, MacPherson R. Synergistic Antidepressant Effects with Ketamine and ECT. J ECT. 2009;25(2):150.
9. McDaniel WW, Sahota AK, Vyas BV, Laguerta N, Hategan L, Oswald J. Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies. J ECT. 2006;22(2):103-6.
10. Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl). 2006;188(4):408-24.
11. Sobin C, Sackeim HA, Prudic J, Devanand DP, Moody BJ, McElhiney MC. Predictors of retrograde amnesia following ECT. Am J Psychiatry. 1995;152(7):995-1001.
12. Wang X, Chen Y, Zhou X, Liu F, Zhang T, Zhang C. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. J ECT. 2012;28(2):128-32.
13. Erdogan Kayhan G, Yucel A, Colak YZ, Ozgul U, Yologlu S, Karlidag R, et al. Ketofol (mixture of ketamine and propofol) administration in electroconvulsive therapy. Anaesth Intensive Care. 2012;40(2):305-10.
14. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959-64.
15. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475(7354):91-5.
16. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17(8):2921-7.
17. Timm C, Linstedt U, Weiss T, Zenz M, Maier C. [Sympathomimetic effects of low-dose S(+)-ketamine. Effect of propofol dosage]. Anaesthesist. 2008;57(4):338-46.
18. Rapeport DA, Martyr JW, Wang LP. The use of "ketofol" (ketaminepropofol admixture) infusion in conjunction with regional anaesthesia. Anaesth Intensive Care. 2009;37(1):121-3.
19. Andolfatto G, Willman E. A prospective case series of singlesyringe ketamine-propofol (Ketofol) for emergency department procedural sedation and analgesia in adults. Acad Emerg Med. 2011;18(3):237-45.
20. Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CJ. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther. 2009;123(2):143-50.
21. Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CJ. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry. 2009;65(2):181-4.
22. Correll GE, Futter GE. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med. 2006;7(1):92-5.
23. Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5):522-6.
24. Goforth HW, Holsinger T. Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. J ECT. 2007;23(1):23-5.
25. Kranaster L, Kammerer-Ciernioch J, Hoyer C, Sartorius A. Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study. Eur Arch Psychiatry Clin Neurosci. 2011;261(8):575-82.
26. Ostroff R, Gonzales M, Sanacora G. Antidepressant effect of ketamine during ECT. Am J Psychiatry. 2005;162(7):1385-6.